Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AAM Warns Over Weakening 180-Day Incentive

20 Mar 2019

• By Dave Wallace

Dartboard — Amending 180-Day Exclusivity Risks Weakening The Incentive • Source: Shutterstock

Related Content

OGD celebrates over a thousand approvals

16 Feb 2018

Pressures on US industry go beyond current price squeeze

02 Nov 2018

Generics Industry Loses 'Champion' As Gottlieb Steps Down

06 Mar 2019

Novitium’s Pyridostigmine Shows Six Appeal Of CGT Pathway

14 Mar 2019

Additional Topics

United States Regulation Generic Drugs

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.